Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DANIEL ALAN KERR II

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1821387135
CMS profile
1098538
Location
TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$68,879.71

155 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DANIEL ALAN KERR II

NPI 1821387135 · CMS profile ID 1098538

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1821387135?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DANIEL ALAN KERR II, NPI 1821387135, CMS profile ID 1098538. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1821387135?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). DANIEL ALAN KERR II, NPI 1821387135, CMS profile ID 1098538. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1821387135?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
DANIEL ALAN KERR II, NPI 1821387135, CMS profile ID 1098538, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 155 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1821387135?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

155 matching records · $68,879.71 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 155 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 155.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Celgene Corporation $25.1904/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015467273 CMS
Daiichi Sankyo Inc. $14.9304/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006354143 CMS
Genentech USA, Inc. $1,560.0004/11/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040336435 CMS
AstraZeneca Pharmaceuticals LP $107.9904/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015374729 CMS
Celgene Corporation $23.4804/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015467309 CMS
Incyte Corporation $18.8603/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044499343 CMS
Genentech USA, Inc. $3,130.0003/25/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040336423 CMS
E.R. Squibb & Sons, L.L.C. $9.0903/24/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015467249 CMS
Genmab U.S., Inc. $119.9003/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051343689 CMS
Genmab U.S., Inc. $25.2103/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051343691 CMS
ABBVIE INC. $86.6903/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997629293 CMS
Bayer Healthcare Pharmaceuticals Inc. $23.1703/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000518117 CMS
Lilly USA, LLC $105.6303/21/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031339323 CMS
Gilead Sciences, Inc. $22.8403/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025713261 CMS
Genentech USA, Inc. $1,052.9503/15/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040336381 CMS
Genentech USA, Inc. $122.4003/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040336387 CMS
Genentech USA, Inc. $5,000.0003/15/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040336393 CMS
Rigel Pharmaceuticals, Inc. $13.6403/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1033390183 CMS
Lilly USA, LLC $6.9203/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031328781 CMS
Mirati Therapeutics, Inc. $20.0103/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057994555 CMS
BeiGene USA, Inc. $125.0003/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051189691 CMS
BeiGene USA, Inc. $4,500.0003/01/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051189693 CMS
Incyte Corporation $19.2403/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044499295 CMS
Seagen Inc. $18.4903/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995796749 CMS
Bayer Healthcare Pharmaceuticals Inc. $17.1602/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000506191 CMS
Sun Pharmaceutical Industries Inc. $20.2402/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053825589 CMS
Janssen Biotech, Inc. $18.3502/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988678225 CMS
Incyte Corporation $68.3602/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044499265 CMS
Merck Sharp & Dohme LLC $19.2902/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048366793 CMS
Rigel Pharmaceuticals, Inc. $12.6502/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1033401793 CMS
AstraZeneca Pharmaceuticals LP $18.8702/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015701999 CMS
EMD Serono, Inc. $23.4202/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032331133 CMS
Kite Pharma, Inc. $16.6202/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025270451 CMS
BeiGene USA, Inc. $7,500.0002/07/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051189689 CMS
PFIZER INC. $13.0202/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050661063 CMS
Eisai Inc. $20.1702/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1023306433 CMS
G1 Therapeutics, Inc. $17.1402/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059917367 CMS
Pharmacyclics LLC, An AbbVie Company $25.4701/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998288395 CMS
Bayer Healthcare Pharmaceuticals Inc. $26.6101/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000523961 CMS
BeiGene USA, Inc. $41.8001/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051189683 CMS
BeiGene USA, Inc. $49.8701/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051189685 CMS
BeiGene USA, Inc. $49.8701/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051189687 CMS
BeiGene USA, Inc. $303.9701/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051189679 CMS
BeiGene USA, Inc. $413.8001/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051189681 CMS
Lilly USA, LLC $14.4101/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031339325 CMS
Janssen Biotech, Inc. $17.6101/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988678227 CMS
Lilly USA, LLC $20.5501/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031349453 CMS
Daiichi Sankyo Inc. $15.6201/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1006378085 CMS
Genentech USA, Inc. $1,515.0001/19/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040336441 CMS
Rigel Pharmaceuticals, Inc. $5.4201/19/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1033407133 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $548.40 26
PY2020 $1,580.85 77
PY2021 $3,368.06 147
PY2022 $9,580.98 124
PY2023 $68,879.71 155
PY2024 $49,120.74 117
PY2025 $59,422.82 112

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $58,377.25 9
PY2024 Principal investigator $197,692.77 18
PY2023 Recipient $1,435.35 1
PY2023 Principal investigator $165,867.74 15
PY2022 Principal investigator $39,539.23 6
PY2021 Principal investigator $13,375.00 2
PY2020 Principal investigator $228.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

9 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $58.00 12/31/2025 Covered Recipient Teaching Hospital
TAMPA GENERAL HOSPITAL
Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1202422413
Principal investigator 1 ABBVIE INC. $16,419.44 12/04/2025 Covered Recipient Teaching Hospital
TAMPA GENERAL HOSPITAL
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1202422410
Principal investigator 1 ABBVIE INC. $17,896.41 11/04/2025 Covered Recipient Teaching Hospital
TAMPA GENERAL HOSPITAL
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1202422405
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,500.00 11/03/2025 Covered Recipient Teaching Hospital
Tampa General Hospital
A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma No dispute reported 06/30/2026 1236000140
Principal investigator 1 ABBVIE INC. $2,852.21 10/09/2025 Covered Recipient Teaching Hospital
TAMPA GENERAL HOSPITAL
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1202422401
Principal investigator 1 ABBVIE INC. $3,477.60 06/03/2025 Covered Recipient Teaching Hospital
TAMPA GENERAL HOSPITAL
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1202422397
Principal investigator 1 ABBVIE INC. $290.25 02/05/2025 Covered Recipient Teaching Hospital
TAMPA GENERAL HOSPITAL
M22-132 - A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma No dispute reported 06/30/2026 1202422394
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $383.34 01/27/2025 Non-covered Recipient Entity
Tampa General Hospital
A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma No dispute reported 06/30/2026 1235993373
Principal investigator 1 Celgene Corporation $13,500.00 01/13/2025 Covered Recipient Teaching Hospital
Tampa General Hospital
A Phase 2 Randomized, Open Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma No dispute reported 06/30/2026 1222305384